Patents by Inventor Roy R. Lobb

Roy R. Lobb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR THE IDENTIFICATION OF BIFUNCTIONAL COMPOUNDS
    Publication number: 20190144503
    Abstract: The present disclosure provides bifunctional compounds including a polypeptide targeting moiety conjugated to a small molecule in a site-specific manner both of which bind to the same target protein resulting in potent and specific binding characteristics and methods of identifying such compounds.
    Type: Application
    Filed: April 27, 2017
    Publication date: May 16, 2019
    Applicant: Regents of the University of Minnesota
    Inventor: Roy R. Lobb
  • Method for the treatment of inflammatory disorders
    Patent number: 9902774
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: February 27, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Antonin De Fougerolles, Philip Gotwals, Roy R. Lobb, Victor E. Kotelianski
  • METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20140154259
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Application
    Filed: September 9, 2013
    Publication date: June 5, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: ANTONIN DE FOUGEROLLES, Philip Gotwals, Roy R. Lobb, Victor E. Kotelianski
  • METHODS OF TREATING CENTRAL NERVOUS SYSTEM ISCHEMIC OR HEMORRHAGIC INJURY USING ANTI ALPHA4 INTEGRIN ANTAGONISTS
    Publication number: 20140127195
    Abstract: Methods of, and compositions for, treating central nervous system injury with an antagonist of an alpha4 subunit containing integrin are described.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jane K. Relton, Roy R. Lobb, Eric T. Whalley, Steve P. Adams
  • METHODS OF TREATING CENTRAL NERVOUS SYSTEM ISCHEMIC OR HEMORRHAGIC INJURY USING ANTI ALPHA4 INTEGRIN ANTAGONISTS
    Publication number: 20130011390
    Abstract: Methods of, and compositions for, treating central nervous system injury with an antagonist of an alpha4 subunit containing integrin are described.
    Type: Application
    Filed: June 6, 2012
    Publication date: January 10, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jane Relton, Roy R. Lobb, Eric Whalley, Steven P. Adams
  • Recombinant anti-VLA4 antibody molecules
    Patent number: 8226950
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: July 24, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Recombinant Anti-VLA4 Antibody Molecules
    Publication number: 20120022236
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Application
    Filed: September 27, 2010
    Publication date: January 26, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Recombinant anti-VLA4 antibody molecules
    Patent number: 7829092
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: November 9, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • RECOMBINANT ANTI-VLA4 ANTIBODY MOLECULES
    Publication number: 20100203042
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Application
    Filed: December 18, 2008
    Publication date: August 12, 2010
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Treatment for asthma with ?4-specific antibodies
    Patent number: 7482003
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: January 27, 2009
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Treatment for inflammatory bowel disease with a fibronectin polypeptide
    Patent number: 7176184
    Abstract: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: February 13, 2007
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Linda C. Burkly
  • Treatment for inflammatory bowel disease with ?4-specific antibodies
    Patent number: 7157086
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: January 2, 2007
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Recombinant anti-VLA-4 antibody molecules
    Publication number: 20030185819
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Application
    Filed: May 2, 2003
    Publication date: October 2, 2003
    Applicant: Biogen, Inc., a Massachusetts corporation
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)
    Publication number: 20030153731
    Abstract: DNA sequences encoding endothelial cell-leukocyte adhesion molecules ELAMs, methods for producing such molecules, and ELAMs (including the specific molecules ELAM1 and VCAM1 and 1b) essentially free of normally associated animal proteins are disclosed. Antibodies against ELAMs are also disclosed.
    Type: Application
    Filed: September 3, 2002
    Publication date: August 14, 2003
    Inventors: Catherine A. Hession, Roy R. Lobb, Susan E. Goelz, Laurelee Osborn, Christopher D. Benjamin, Margaret D. Rosa
  • Recombinant anti-VLA-4 antibody molecules
    Patent number: 6602503
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: August 5, 2003
    Assignee: Biogen, Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Treatment for inflammatory bowel disease with a fibronectin polypeptide
    Publication number: 20030095969
    Abstract: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.
    Type: Application
    Filed: September 23, 2002
    Publication date: May 22, 2003
    Applicant: Biogen,Inc., a Massachusetts corporation
    Inventors: Roy R. Lobb, Linda C. Burkly
  • Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein
    Patent number: 6482409
    Abstract: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of a VCAM-1/IgG fusion protein.
    Type: Grant
    Filed: September 21, 1998
    Date of Patent: November 19, 2002
    Assignee: Biogen, Inc.
    Inventors: Roy R. Lobb, Linda C. Burkly
  • VCAM fusion proteins and DNA coding therefor
    Patent number: 6307025
    Abstract: VCAM fusion proteins capable of binding to VLA4, and DNA molecules coding on these fusions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 23, 2001
    Assignee: Biogen, Inc.
    Inventors: Catherine A. Hession, Roy R. Lobb, Susan E. Goelz, Laurelee Osborn, Christopher D. Benjamin, Margaret D. Rosa
  • Vascular cell adhesion molecule (VCAM) polypeptides
    Patent number: 6252043
    Abstract: VCAM1 polypeptides and VCAM11/ICAM fusion proteins are disclosed.
    Type: Grant
    Filed: September 22, 1994
    Date of Patent: June 26, 2001
    Assignee: Biogen, Inc.
    Inventors: Catherine A. Hession, Roy R. Lobb, Susan E. Goelz, Laurelee Osborn, Christopher D. Benjamin, Margaret D. Rosa
  • Treatment for inflammatory bowel disease with VLA-4 blockers
    Patent number: 5932214
    Abstract: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: August 3, 1999
    Assignee: Biogen, Inc.
    Inventors: Roy R. Lobb, Linda C. Burkly